EV+P Benefit Continues in Metastatic Urothelial Cancer ...Middle East

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to enfortumab vedotin and pembrolizumab. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( EV+P Benefit Continues in Metastatic Urothelial Cancer )

Also on site :

• Death toll in Iran port explosion mounts to 25
• Mass shooting in Myrtle Beach tourist hotspot leaves 11 injured, suspect killed by police
• What happens after Pope Francis funeral – how the Conclave to select his successor will work